Yonsei University

Wan Namkung

Sang Won Lee

Ikyon Kim

Chin Hee Mun

Yo Han Seo

Ik Yon Kim

Jin Hwang Kim

Yohan Seo

Jonghyuk Sung

The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis.

Composition comprising punicalagin for inhibiting PAR2 activity

The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).

Pharmaceutical composition for ANO1 antagonist with anticancer activity

Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells.

Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient

Growing community of inventors

Incheon, South Korea

Wan Namkung